Corroborating these results, T cell-killing assays also showed that CD8+ T cells harvested from NAFLD-HCC have tumor cell-killing ability (Figures 6F, 6G, and S6F), which was suppressed by cholesterol supplementation in a dose-dependent manner (Figure 6G). The gene discussed is CD8A; the disease is metabolic dysfunction-associated steatotic liver disease.